Highlights Alnylam Pharmaceuticals, Inc. Börse Stuttgart

Equities

DUL

US02043Q1076

Market Closed - Börse Stuttgart Other stock markets 10:14:12 2024-06-28 EDT			5-day change	1st Jan Change
227.6 ^EUR	-1.47%		+55.68%	+29.61%

06-28	UBS Adjusts Price Target on Alnylam Pharmaceuticals to $288 From $253, Maintains Buy Rating	MT
06-27	Stifel Adjusts Price Target on Alnylam Pharmaceuticals to $295 From $215, Maintains Buy Rating	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Ease Late Afternoon	06-25	MT
Alnylam Pharmaceuticals Shares Rise as Heart Disease Candidate Meets Primary Endpoint in Late-Stage Study	06-25	MT
Sector Update: Health Care Stocks Rise in Late Afternoon Trading	06-24	MT
Top Midday Gainers	06-24	MT
Alnylam Pharmaceuticals Says Heart Disease Therapy Meets Primary Endpoint in Late-Stage Study	06-24	MT
Alnylam's heart disease drug meets main goal in late-stage study	06-24	RE
Alnylam Pharmaceuticals, Inc. Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations	06-24	CI
Alnylam Pharmaceuticals' Q1 Non-GAAP Net Loss Narrows as Revenue Increases; 2024 Outlook Affirmed	05-02	MT
Earnings Flash (ALNY) ALNYLAM PHARMACEUTICALS Posts Q1 Revenue $494.3M, vs. Street Est of $426.9M	05-02	MT
Alnylam Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-02	CI
Alnylam Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024	05-02	CI
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of Their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in Additional Latam and APAC Markets Including Australia	04-30	CI
Sector Update: Health Care Stocks Flat to Higher Premarket Monday	04-08	MT
Sector Update: Health Care	04-08	MT
Alnylam Pharmaceuticals Says Phase 2 Trial for Zilebesiran Meets Primary Endpoint	04-08	MT
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension	04-07	CI
Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran Is Added to Standard of Care Antihypertensives	03-05	CI
How long will this bullish phase last?	02-26
North American Morning Briefing : Earnings Back in -2-	02-20	DJ
Alnylam Pharmaceuticals' Shares Fall on Q4 Revenue Miss	02-15	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Alnylam Pharmaceuticals, Inc. Börse Stuttgart

Equities

DUL

US02043Q1076

Highlights

Filters